NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer Planned

Publication
Article
OncologyONCOLOGY Vol 14 No 4
Volume 14
Issue 4

The National Institutes of Health (NIH) is sponsoring a Consensus Development Conference on Adjuvant Therapy for Breast Cancer, to be held in Bethesda, Maryland, on November 1-3, 2000.

The National Institutes of Health (NIH) is sponsoring a Consensus Development Conference on Adjuvant Therapy for Breast Cancer, to be held in Bethesda, Maryland, on November 1-3, 2000.

The conference will focus on new data on chemotherapy, hormonal therapy, and other aspects of treatment that have emerged over the past decade since the last consensus conference, and will culminate in the formulation of recommendations for clinical practice.

During the conference, a panel of experts (from outside of the NIH) will hear presentations from leading researchers and then consider questions on specific topics, such as the selection of chemotherapy, radiation therapy, and hormonal therapy. The agenda will also include the clinical use of prognostic markers and quality-of-life issues. Both node-negative and node-positive breast cancers will be discussed.

Health professionals, researchers, patient advocates, and other members of the public may register to attend the by sending an e-mail to breastcancer@prospectassoc.com or by going to the NIH web site for consensus conferences found at http://odp.od.nih.gov/consensus. Additional information is available by calling (301) 592-3320.

Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table